Why CELMoD Agents Emerged After the IMiD Era

Cereblon E3 ligase modulators — CELMoDs — represent a deliberate scientific response to the ceiling imposed by first- and second-generation immunomodulatory drugs (IMiDs) in multiple myeloma. Lenalidomide and pomalidomide transformed myeloma outcomes over two decades, but their clinical utility is ultimately constrained by the development of cereblon pathway resistance and the fact that patients who become refractory to these agents face markedly worse prognoses. CELMoDs are engineered to overcome precisely this barrier: by binding the cereblon protein with substantially greater affinity, they drive more potent and selective degradation of the oncogenic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) that sustain myeloma cell survival.

The mechanistic logic is straightforward but the pharmacological execution is demanding. IMiDs act as “molecular glue” — they do not merely inhibit cereblon but rather reshape its substrate-binding surface to recruit neosubstrates for ubiquitination and subsequent proteasomal destruction. CELMoDs take this same principle and optimise the chemical structure to achieve tighter cereblon binding, faster neosubstrate recruitment, and degradation kinetics that remain effective even when prior IMiD exposure has partially desensitised the pathway. According to research published by Nature, targeted protein degradation strategies of this kind represent one of the most productive areas of oncology drug discovery in the current decade.

The clinical imperative is equally clear. As lenalidomide has migrated to frontline and maintenance therapy — a shift driven by landmark trials and endorsed by guidelines from ASCO and the European Medicines Agency — the proportion of patients entering the relapsed/refractory setting who are already lenalidomide-refractory has grown substantially. This creates a structural treatment gap that CELMoD agents, with their retained activity in IMiD-refractory disease, are specifically designed to fill.

Iberdomide: Mechanism, Potency, and the BMS-986325 Profile

Iberdomide (development code BMS-986325) is Bristol Myers Squibb’s lead CELMoD compound and the most advanced agent of its class in Phase III development for multiple myeloma. Iberdomide binds the cereblon protein — a substrate receptor of the CRL4 ubiquitin E3 ligase complex — with markedly greater affinity than lenalidomide, and this enhanced binding drives deeper, faster, and more sustained degradation of Ikaros (IKZF1) and Aiolos (IKZF3), two transcription factors that are essential for myeloma cell survival and proliferation.

The distinction between iberdomide and its IMiD predecessors is not merely incremental. In preclinical models, iberdomide demonstrated the ability to degrade IKZF1 and IKZF3 in myeloma cell lines that had become resistant to lenalidomide — a finding that underpins the entire clinical rationale for the EXCALIBER-RRMM trial. Importantly, iberdomide also retains immunostimulatory activity, enhancing T-cell and natural killer (NK) cell function, which may synergise with anti-CD38 monoclonal antibodies and other immunotherapeutic backbones increasingly used in myeloma combination regimens.

“Iberdomide’s higher cereblon-binding affinity enables degradation of Ikaros and Aiolos in lenalidomide-refractory myeloma cells — the mechanistic foundation for its role as a post-IMiD successor in the EXCALIBER-RRMM Phase III programme.”

Bristol Myers Squibb’s development strategy for iberdomide reflects a broader industry pattern of building next-generation agents within established mechanistic classes. This approach — sometimes called “class succession” — allows companies to extend commercial and clinical franchises beyond the patent life of earlier agents. The PatSnap pharmaceutical intelligence platform tracks over 2 billion data points across global patent filings, clinical trial registrations, and drug pipeline disclosures, providing R&D teams with the landscape visibility needed to position assets like iberdomide within competitive CELMoD development programmes.

EXCALIBER-RRMM: Trial Design and Patient Population

The EXCALIBER-RRMM trial is a Phase III randomised controlled study evaluating iberdomide in combination with dexamethasone (Iber-d) against standard-of-care comparator regimens in adult patients with relapsed or refractory multiple myeloma who have received prior lenalidomide-containing therapy. As a Phase III programme, EXCALIBER-RRMM is designed to generate the definitive efficacy and safety data required for regulatory submission — moving iberdomide from a promising early-phase signal into a potential approved therapy.

The trial’s comparator design reflects the evolving standard of care in relapsed/refractory multiple myeloma (RRMM). Patients in this setting typically receive triplet or quadruplet regimens incorporating proteasome inhibitors (such as bortezomib or carfilzomib), anti-CD38 antibodies (such as daratumumab or isatuximab), and, where possible, additional immunomodulatory agents. By positioning Iber-d against these established regimens, EXCALIBER-RRMM is designed to demonstrate not merely non-inferiority but clinically meaningful superiority in a patient population with limited remaining options.

The patient population enrolled in EXCALIBER-RRMM is clinically important. These are individuals who have already received lenalidomide — most likely as part of frontline induction and/or maintenance — and whose disease has subsequently relapsed or become refractory. This is an increasingly common clinical scenario as lenalidomide-based frontline therapy has become near-universal in transplant-eligible and transplant-ineligible patients alike, in line with guidance from regulatory agencies including the US Food and Drug Administration.

Patent Landscape and Competitive Intelligence Around CELMoDs

The CELMoD patent landscape is one of the most actively contested areas in oncology intellectual property. Bristol Myers Squibb holds foundational patent positions covering iberdomide’s core chemical structure, its cereblon-binding mechanism, and its use in combination regimens — a portfolio that reflects the company’s strategic intent to establish CELMoDs as the successor franchise to its lenalidomide and pomalidomide businesses. Understanding this patent estate is essential for R&D leaders, business development professionals, and IP counsel navigating the myeloma competitive landscape.

Beyond iberdomide, the CELMoD space includes additional agents at earlier stages of development, as well as related targeted protein degradation technologies — including proteolysis-targeting chimeras (PROTACs) and molecular glue degraders — that may eventually compete in overlapping clinical indications. Patent filings in this space have accelerated markedly, with academic institutions, large pharma, and specialist biotechnology companies all staking claims across cereblon-binding chemical series, neosubstrate degradation methods, and combination use cases. The PatSnap innovation intelligence platform provides comprehensive mapping of these filings across WIPO, USPTO, EPO, and national patent offices worldwide.

Key patent strategy questions in the CELMoD space include: the expiry timeline of composition-of-matter claims covering iberdomide itself; the breadth of method-of-use claims protecting specific combination regimens; the freedom-to-operate position for biosimilar and generic developers eyeing post-exclusivity entry; and the extent to which next-generation CELMoD structures from competitors can design around BMS’s core claims. These are not abstract legal questions — they directly determine the commercial duration of iberdomide’s market opportunity and the timing of competitive threats.

Implications for Myeloma Treatment Sequencing Post-Lenalidomide

A positive EXCALIBER-RRMM result would reshape treatment sequencing in multiple myeloma by establishing iberdomide as the preferred agent for patients who have progressed on or become refractory to lenalidomide-based regimens. This matters because treatment sequencing in myeloma is not merely a clinical decision — it is a commercial and regulatory one, with payer formularies, national health technology assessments, and clinical guideline committees all playing roles in determining which agents patients actually receive after frontline therapy.

The broader implication of CELMoD succession is that the IMiD class — which has dominated myeloma therapy for over two decades — may be superseded not by an entirely different mechanism but by an optimised iteration of the same fundamental biology. This has precedent in oncology: second-generation tyrosine kinase inhibitors succeeded imatinib in CML; third-generation EGFR inhibitors followed first- and second-generation agents in non-small cell lung cancer. In each case, the successor agent retained the core mechanism while overcoming the specific resistance mechanisms that limited its predecessor. Iberdomide’s development follows the same logic with respect to lenalidomide and the cereblon pathway.

For pharmaceutical companies, biotech investors, and IP strategists, the EXCALIBER-RRMM readout will serve as a critical inflection point — not only for iberdomide itself but for the entire class of cereblon-targeting degraders. A successful Phase III result would validate CELMoDs as a durable commercial and clinical category, likely accelerating investment in next-generation CELMoD structures and combination strategies. Conversely, it would also intensify patent litigation and inter partes review activity as competitors seek to design around BMS’s foundational claims. Monitoring these developments requires the kind of integrated drug, patent, and clinical trial intelligence available through platforms like PatSnap’s life sciences intelligence suite.

For clinical teams, the sequencing question is also about tolerability. Patients in the post-lenalidomide relapsed/refractory setting have typically received multiple prior lines of therapy and carry a cumulative toxicity burden. Iberdomide’s differentiated safety profile — informed by Phase I/II data — will be scrutinised closely in the EXCALIBER-RRMM Phase III context, particularly with respect to haematological toxicities, infection risk, and quality-of-life measures that increasingly influence payer and prescriber decisions in late-line myeloma.